吸入型奥匹康唑体外与临床数据表明药物相互作用风险可忽略
吸入型奥匹康唑是研发中用于治疗肺曲霉病的抗真菌药。体外研究显示其对CYP的相互作用仅限于CYP3A4竞争性抑制及CYP3A4/CYP1A2弱诱导潜力,且发生在高于临床稳态浓度的水平。Ⅰ期健康志愿者研究证实,吸入奥匹康唑达稳态时对CYP3A4和CYP1A2无抑制/诱导作用,与上述底物合用时的相互作用潜力可忽略。
要点
- 体外相互作用仅见于高于临床稳态浓度的奥匹康唑水平。
- Ⅰ期研究显示稳态吸入奥匹康唑对CYP3A4和CYP1A2无抑制/诱导。
- 临床给药后全身稳态浓度不太可能导致CYP或转运体介导的药物相互作用。
核心结论
- 临床给药后吸入奥匹康唑达到的全身稳态浓度不太可能引起CYP介导或转运体介导的药物相互作用。
研究设计与样本
- 体外研究评估奥匹康唑对CYP同工酶及人转运蛋白的相互作用。
- Ⅰ期健康志愿者研究评估每日重复吸入奥匹康唑对CYP1A2和CYP3A4的抑制或诱导,分别以咖啡因和咪达唑仑为底物。
主要发现
- 体外分析显示奥匹康唑与人CYP的相互作用仅限于对CYP3A4的竞争性抑制及对CYP3A4和CYP1A2的弱诱导潜力,且发生在高于临床给药后预期稳态浓度的水平。
- 对有限范围转运蛋白的抑制出现在微摩尔浓度的奥匹康唑,但未发现其为载体转运体的底物。
- Ⅰ期健康志愿者研究中,吸入奥匹康唑达稳态时对CYP3A4或CYP1A2无抑制/诱导,总体耐受良好。
临床怎么用
- 吸入奥匹康唑临床给药后全身稳态浓度下,与CYP3A4和CYP1A2底物合用时预计药物相互作用风险可忽略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Invasive fungal diseases (IFDs) cause high morbidity and mortality among immune-compromised patients. Triazoles, which are recommended to treat IFDs, inhibit and/or are substrates for the phase 1 cytochrome P450 (CYP) pathway that metabolizes many drugs and frequently result in drug-drug interactions (DDIs). Nebulized opelconazole is an investigational inhaled antifungal in development for the treatment of pulmonary aspergillosis. METHODS: In vitro studies first assessed effects of opelconazole on CYP isoforms and human transporter protein interactions. Subsequently, a Phase 1 study in healthy volunteers assessed whether repeat daily dosing of inhaled opelconazole inhibited or induced CYP1A2 and CYP3A4 using the substrates caffeine and midazolam, respectively. RESULTS: In vitro analyses confirmed that opelconazole interactions with human CYPs were limited to competitive inhibition of CYP3A4 and weak induction potential for CYP3A4 and CYP1A2. These interactions occurred at concentrations higher than those expected at steady state following clinical dosing. Inhibition of a limited range of transporter proteins occurred at micromolar concentrations of opelconazole, but it was not found to be a substrate for carrier transporters. In the Phase 1 healthy volunteer study, inhaled opelconazole at steady state demonstrated no inhibition/induction of CYP3A4 or CYP1A2 and was generally well tolerated. The Phase 1 study results confirmed that the potential for interactions of opelconazole with CYP3A4 and CYP1A2 substrates during concomitant use was negligible. CONCLUSIONS: Systemic steady-state concentrations achieved after clinical dosing of inhaled opelconazole are unlikely to be associated with CYP-mediated DDIs or transporter-mediated DDIs.
引用
- Cass LMR, Ayrton J, Brüggemann RJ, et al. In vitro and clinical data demonstrate negligible risk of drug-drug interactions with opelconazole, a novel inhaled antifungal agent. J Antimicrob Chemother. 2025. PMID: 41105437. doi:10.1093/jac/dkaf384
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。